Department of Cardiology, The Second Hospital of Hebei Medical University, Hebei, China.
Department of Cardiology, The First Affilliated Hospital of Hebei North University, Hebei, China.
J Coll Physicians Surg Pak. 2022 May;32(5):559-564. doi: 10.29271/jcpsp.2022.05.559.
To assess the effects of trimetazidine (TMZ) added to conventional drug therapy on cardiac autonomic nervous CANS in patients with coronary heart disease (CHD) after the percutaneous coronary intervention (PCI).
Descriptive study.
Department of Cardiology, The Second Hospital of Hebei Medical University, Hebei, China, from May 2018 to September 2019.
The study included 50 patients with CHD after a successful PCI who received trimetazidine plus conventional therapy were included as cases (exposed group), and 50 matched patients were identified as controls (non-exposed group). Heart rate (HR) and heart rate variability (HRV) parameters including sympathetic activity (SDNN, LF), parasympathetic activity (RMSSD, pNN50, SDSD, HF), and sympathovagal balance (LF/HF ratio) were used to evaluate CANS function.
There were no statistical differences in the HR and HRV parameters before and after PCI (p>0.05). In the non-exposed group, conventional therapy significantly improved the HRV parameters (all p<0.05), while not affecting HR (p>0.05). In the exposed group, all HRV parameters except HR were improved after 4 weeks of treatment. After 4 weeks of treatment, the exposed group had higher parasympathetic-nerve activity, lower sympathetic-nerve activity, and LF/HF ratio compared to the non-exposed group (all p<0.05).
The application of TMZ based on conventional therapy effectively improved the CANS in CHD patients who underwent PCI.
Coronary heart disease, Percutaneous coronary intervention, Trimetazidine, Cardiac autonomic nervous system, Heart rate variability.
评估曲美他嗪（TMZ）联合常规药物治疗对经皮冠状动脉介入治疗（PCI）后冠心病（CHD）患者心脏自主神经 CANS 的影响。
描述性研究。
中国河北医科大学第二医院心内科，2018 年 5 月至 2019 年 9 月。
该研究纳入了 50 例成功 PCI 后 CHD 患者，接受曲美他嗪加常规治疗的患者为病例组（暴露组），并选择 50 例匹配患者为对照组（非暴露组）。采用心率（HR）和心率变异性（HRV）参数，包括交感神经活性（SDNN、LF）、副交感神经活性（RMSSD、pNN50、SDSD、HF）和交感神经-副交感神经平衡（LF/HF 比值）来评估 CANS 功能。
PCI 前后 HR 和 HRV 参数无统计学差异（p>0.05）。在非暴露组中，常规治疗显著改善了 HRV 参数（均 p<0.05），而对 HR 无影响（p>0.05）。在暴露组中，除 HR 外，所有 HRV 参数在治疗 4 周后均得到改善。治疗 4 周后，暴露组的副交感神经活性较高，交感神经活性较低，LF/HF 比值低于非暴露组（均 p<0.05）。
在常规治疗的基础上应用 TMZ 可有效改善 PCI 后 CHD 患者的 CANS。
冠心病、经皮冠状动脉介入治疗、曲美他嗪、心脏自主神经、心率变异性。
